Clinical Research Directory
Browse clinical research sites, groups, and studies.
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
Sponsor: Indiana University
Summary
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.
Official title: Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-02-18
Completion Date
2026-09-30
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
SYSTANE® PRO
SYSTANE® PRO is a preservative free artificial tear with a unique triple action formula that contains hyaluronate, nano-sized lipids, and HP-Guar.
MIEBO™ (Perfluorohexyloctane, PFHO)
Perfluorohexyloctane (PFHO) ophthalmic solution, which is marketed in the United States as MIEBO™ (Bausch + Lomb; Rochester, NY, USA) is a preservative-free eye drop.
Locations (4)
Eye Research Foundation
Newport Beach, California, United States
Indiana Universtiy School of Optometry
Bloomington, Indiana, United States
Kannarr Eye Care
Pittsburg, Kansas, United States
Southern College of Optometry
Memphis, Tennessee, United States